ALX Oncology Holdings Inc.
- ALXO
- NASDAQ
- Biotechnology
- Immuno-Oncology
- CD47 Inhibitor
$1.06
Today +6.00%Quote Oct 16, 2026, 08:00 PM UTC
−39.08%over the last month
Max drawdown −48.6%From 1-month high −39.1%3 months −44.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$146.6M
Quote Oct 16
Next earnings
Nov 6
Expected, not confirmed
Analyst target
$17.90
+1588.7% from here
Floor
$1.03
2.6% below price
Where the price sits
7 analysts
Analyst range, low to high
$1.50$38.00
- Price $1.06
- Resistance $1.12
- Consensus $17.90
Analysts' average target sits about 1589% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ALXOPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
48
Founded
2015